March 21, 2024

The U.S. Food and Drug Administration (FDA) published a paper March 15, to update the public about intra-agency activities to oversee artificial intelligence (AI)-enabled healthcare technologies. The paper summarizes priorities shared across the biologics, drugs and medical devices domains of FDA jurisdiction.

Four general focus areas are discussed: fostering collaboration with stakeholders; developing appropriate regulatory approaches; promoting development of standards and best practices; and supporting research on performance evaluation. Moving forward, the FDA intends to evolve its own regulatory approaches with the continued progression of AI tools.

For more information about various American College of Radiology®(ACR®) AI-specific initiatives, visit the ACR Data Science Institute®. For more information about FDA oversight and digital health policy, contact Michael Peters, ACR Senior Government Affairs Director.


Related ACR News

  • House Committee Includes Medicare Payment Reform in Budget Bill

    The U.S. House Committee on Energy and Commerce reported its section of the federal budget reconciliation bill out of committee.

    Read more
  • 2025 MIPS Exception Applications Now Available

    CMS announced Quality Payment Program exception applications are available now through Dec. 31.

    Read more
  • Radiology in AI Highlighted at ACR 2025

    Read more